Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer
Jeffrey How(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Pamela T. Soliman(The University of Texas MD Anderson Cancer Center), Lois M. Ramondetta(The University of Texas MD Anderson Cancer Center), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Nicole D. Fleming(The University of Texas MD Anderson Cancer Center), Shrina Patel(The University of Texas MD Anderson Cancer Center), Patrick Hwu(Moffitt Cancer Center)
Cited by 56
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
|Nature Medicine|2023|508